Data Sheet 1_Efficacy and safety of combining commercial Chinese polyherbal preparation wi

A systematic review and network meta-analysis of 67 randomized controlled trials involving 6,139 patients, conducted by Xiaoying Guo and published in 2026. The study compares the efficacy and safety of 19 commercial Chinese polyherbal preparations combined with conventional medicine for treating coronary microvascular disease.

Use Cases

• Ranking treatment efficacy for coronary microvascular disease based on outcomes like microcirculatory resistance and coronary flow reserve.
• Comparing the safety profiles of different Chinese polyherbal preparations based on reported adverse event rates.
• Identifying optimal treatment combinations for specific clinical endpoints such as left ventricular ejection fraction or inflammatory markers.
• Informing the design of future high-quality clinical trials for coronary microvascular disease treatments.

Strengths

• Analysis is based on 67 randomized controlled trials, providing a substantial evidence base.
• Includes data from 6,139 patients, offering a meaningful sample size for meta-analysis.
• Compares 19 distinct commercial Chinese polyherbal preparations across multiple clinical outcomes.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The authors note the initial results require confirmation through high-quality, rigorously designed clinical trials.

Provenance

Source

figshare

Collection Method

Systematic review and network meta-analysis of published randomized controlled trials.

Time Range

Studies searched through November 2025.

Freshness

Last updated 2026-06-04 05:42:51